Market Overview

UPDATE: Piper Jaffray Raises PT to $27 on Pacira Pharmaceuticals on Strong Exparel Data Points

Related PCRX
5 Specialty Pharma Stocks Nomura Is Picking To Weather The Storm
Wedbush Thinks Pacira Pharma Is Worth $106 On Exparel Sales

Piper Jaffray reiterated its Overweight rating on Pacira Pharmaceuticals (NASDAQ: PCRX) and raised the price target from $22.00 to $27.00.

Piper Jaffray noted, “Data points for Pacira's Exparel continue to look favorable, reinforcing our confidence in a strong sales ramp for 2013 and beyond. Institutional sales (wholesale acquisition cost (WAC)-based sales, per Wolters Kluwer (WK), via Bloomberg) for Exparel for December 2012 were around $2.76M, compared to $1.67M in November. Though third party sources generally have done an uneven job of capturing demand, the directional trends dovetail with PCRX's bullish commentary regarding hospital acceptance. We remain confident in our Exparel sales estimates of $70M and $146M in 2013 and 2014, respectively.”

Pacira Pharmaceuticals closed at $19.88 on Friday.

Latest Ratings for PCRX

Oct 2015Leerink SwannMaintainsMarket Perform
Sep 2015NomuraInitiates Coverage onBuy
Jul 2015Bank of AmericaUpgradesUnderperformNeutral

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (PCRX)

Get Benzinga's Newsletters